- Home
- CYH vs ALT Comparison
CYH vs ALT Comparison
Compare CYH & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | ALT |
|---|---|---|
| Founded | 1985 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.3M | 421.5M |
| IPO Year | 2000 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CYH | ALT |
|---|---|---|
| Price | $2.98 | $2.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $3.28 | ★ $17.67 |
| AVG Volume (30 Days) | 1.7M | ★ 4.8M |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 196.67 | 25.37 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $12,485,000,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.17 | N/A |
| P/E Ratio | $32.44 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $2.41 | $2.56 |
| 52 Week High | $4.43 | $6.44 |
Technical Indicators
Market Signals| Indicator | CYH | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 49.06 |
| Support Level | $2.89 | $2.80 |
| Resistance Level | $2.99 | $3.09 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 57.18 | 30.56 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.